<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
  • Menu
  • crown-logo-symbol-1-400x551

Find it Quickly

Get Started

Select the option that best describes what you are looking for

  • Services
  • Models
  • Scientific Information

Search Here For Services

Click Here to Start Over

Search Here For Models

Click Here to Start Over

Search Here For Scientific Information

Click Here to Start Over

In Vitro

Boost oncology drug discovery with XenoBase®, featuring the largest cell line selection and exclusive 3D organoid models. Benefit from OrganoidXplore™ and OmniScreen™ for rapid, in-depth analysis.

Learn More

In Vivo

Enhance drug development with our validated in vivo models, in vitro/ex vivo assays, and in silico modeling. Tailored solutions to optimize your candidates.

Learn More

Tissue

Experience ISO-certified biobanking quality. Access top biospecimens from a global clinical network, annotated by experts for precise research.

Learn More

Biomarkers and Bioanalysis

Leverage our global labs and 150+ scientists for fast, tailored project execution. Benefit from our expertise, cutting-edge tech, and validated workflows for reliable data outcomes.

Learn More

Data Science and Bioinformatics

Harness your data and discover biomarkers with our top bioinformatics expertise. Maximize data value and gain critical insights to accelerate drug discovery and elevate projects.

Learn More

KRAS

Accelerate innovative cancer treatments with our advanced models and precise drug screening for KRAS mutations, efficiently turning insights into clinical breakthroughs.

Learn More

EGFR

Advance translational pharmacology with our diverse pre-clinical models, robust assays, and data science-driven biomarker analysis, multi-omics, and spatial biology.

Learn More

Drug Resistance

Our suite integrates preclinical solutions, bioanalytical read-outs, and multi-omics to uncover drug resistance markers and expedite discovery with our unique four-step strategy.

Learn More

Patient Tissue

Enhance treatments with our human tumor and mouse models, including xenografts and organoids, for accurate cancer biology representation.

Learn More

Bioinformatics

Apply the most appropriate in silico framework to your pharmacology data or historical datasets to elevate your study design and analysis, and to improve your chances of clinical success.

Learn More

Biomarker Analysis

Integrate advanced statistics into your drug development projects to gain significant biological insight into your therapeutic candidate, with our expert team of bioinformaticians.

Learn More

CRISPR/Cas9

Accelerate your discoveries with our reliable CRISPR solutions. Our global CRISPR licenses cover an integrated drug discovery platform for in vitro and in vivo efficacy studies.

Learn More

Genomics

Rely on our experienced genomics services to deliver high quality, interpretable results using highly sensitive PCR-based, real-time PCR, and NGS technologies and advanced data analytics.

Learn More

In Vitro High Content Imaging

Gain more insights into tumor growth and disease progression by leveraging our 2D and 3D fluorescence optical imaging.

Learn More

Mass Spectrometry-based Proteomics

Next-generation ion mobility mass spectrometry (MS)-based proteomics services available globally to help meet your study needs.

Learn More

Ex Vivo Patient Tissue

Gain better insight into the phenotypic response of your therapeutic candidate in organoids and ex vivo patient tissue.

Learn More

Spatial Multi-Omics Analysis

Certified CRO services with NanoString GeoMx Digital Spatial Profiling.

Learn More

Biomarker Discovery

De-risk your drug development with early identification of candidate biomarkers and utilize our biomarker discovery services to optimize clinical trial design.

Learn More

DMPK Services

Rapidly evaluate your molecule’s pharmaceutical and safety properties with our in vivo drug metabolism and pharmacokinetic (DMPK) services to select the most robust drug formulations.

Learn More

Efficacy Testing

Explore how the novel HuGEMM™ and HuCELL™ platforms can assess the efficacy of your molecule and accelerate your immuno-oncology drug discovery programs.

Learn More

Laboratory Services

Employ cutting-edge multi-omics methods to obtain accurate and comprehensive data for optimal data-based decisions.

Learn More

Pharmacology & Bioanalytical Services

Leverage our suite of structural biology services including, recombinant protein expression and protein crystallography, and target validation services including RNAi.

Learn More

Screens

Find the most appropriate screen to accelerate your drug development: discover in vivo screens with MuScreen™ and in vitro cell line screening with OmniScreen™.

Learn More

Toxicology

Carry out safety pharmacology studies as standalone assessments or embedded within our overall toxicological profiling to assess cardiovascular, metabolic and renal/urinary systems.

Learn More

Our Company

Global CRO in California, USA offering preclinical and translational oncology platforms with high-quality in vivo, in vitro, and ex vivo models.

Learn More

Our Purpose

Learn more about the impact we make through our scientific talent, high-quality standards, and innovation.

Learn More

Our Responsibility

We build a sustainable future by supporting employee growth, fostering leadership, and exceeding customer needs. Our values focus on innovation, social responsibility, and community well-being.

Learn More

Meet Our Leadership Team

We build a sustainable future by fostering leadership, employee growth, and exceeding customer needs with innovation and social responsibility.

Learn More

Scientific Advisory Board

Our Scientific Advisory Board of experts shapes our strategy and ensures top scientific standards in research and development.

Learn More

News & Events

Stay updated with Crown Bioscience's latest news, achievements, and announcements. Check our schedule for upcoming events and plan your visit.

Learn More

Career Opportunities

Join us for a fast-paced career addressing life science needs with innovative technologies. Thrive in a respectful, growth-focused environment.

Learn More

Scientific Publications

Access our latest scientific research and peer-reviewed articles. Discover cutting-edge findings and insights driving innovation and excellence in bioscience.

Learn More

Resources

Discover valuable insights and curated materials to support your R&D efforts. Explore the latest trends, innovations, and expertly curated content in bioscience.

Learn More

Blogs

Explore our blogs for the latest insights, research breakthroughs, and industry trends. Stay educated with expert perspectives and in-depth articles driving innovation in bioscience.

Learn More

  • Platforms
  • Target Solutions
  • Technologies
  • Service Types

Large-Scale Immunotherapy Screening: How and Why?

Representative immunotherapy and combination regimen screening using immunocompetent syngeneic or tumor homograft models

Representative immunotherapy and combination regimen screening using immunocompetent syngeneic or tumor homograft modelsLearn more about the need for large-scale cancer immunotherapy screens and the different immunocompetent models available for screening.

Why Are Large-Scale Screens Needed for Immunotherapy Development?

Immunotherapies and combination regimens are complex in nature. Their comprehensive preclinical testing in relevant immuno-oncology models is critical to evaluate efficacy and pharmacodynamics (PD), as well as uncover any potential safety issues or optimize treatment regimens before clinical trials.

One route for evaluating new immunotherapies and combination regimens is through large-scale I/O screens. These screening platforms are increasingly relevant for a number of reasons, including variability due to individual immune signatures and a need for a variety of model types.

Within preclinical studies, inter- and intra-group variability occurs due to the complexity of the immune system and its interactions with the environment and tumor in a living organism. For example, although mice used within a syngeneic study have the same genetic makeup, individual mice have their own unique immune signatures. This inherent variability results in varying responses to the same treatment, calling for scalable preclinical models that can provide sufficient ‘n’ for meaningful analyses.

There’s also a need for a variety of model types to understand the effectiveness of your I/O agent in diverse molecular and tumor immune microenvironments. We don't always know why some patients respond and others don't. Therefore, using a variety of model types with different molecular drivers and tumor immune environments in large-scale allows the investigation of mechanism of actions, PD effects, and potentially discovery of predictive biomarkers.

Immunocompetent Models for Immuno-Oncology Screening

Syngeneic Models

The main model type being used for immunotherapy screens are syngeneic models, still often considered the “workhorse” of I/O studies. Syngeneics are mouse cancer cell lines grown in a fully immune competent host with the same genetic background.

One key advantage of syngeneic models is that they can be quickly established in large numbers. In addition, there is a wealth of historical data available for comparison, as syngeneic models have been around for several decades.

Most importantly, syngeneic models represent the range of immune profiles observed in the clinic, making them an ideal platform for large-scale screening of immune modulating agents.

Syngeneic models have been widely used to perform proof of concept studies by testing the in vivo efficacy of a compound in order to identify responder and non-responder models. They can also be used to assess the PD effect of a compound on the immune profile of tumor, blood, and immune relevant organs, uncover predictive biomarkers, and understand mechanisms of action.

The Need for Alternative Immunocompetent Models

While syngeneics do provide a good start pointing for I/O screening, the hard truth is that there are only a limited number of models available. As they’ve been passaged in vitro during derivation from immortalized cell lines there’s also the risk of genetic drift and enhanced tumor mutational burden.

For some indications, syngeneics are simply not the best models for efficacy testing due to a lack of specific, disease relevant mutations and TME. For instance, Pan02 is a commonly used pancreatic cancer syngeneic model, but it lacks KRAS mutations which are seen in >90% of human pancreatic cancers.

Tumor Homograft Models

Tumor homograft models provide a novel new alternative for immunotherapy screening. They are derived from GEMM or carcinogen-induced tumors that harbor clinically-relevant oncogenic driver mutations such as KRAS, p53, and PTEN. Similar to traditional syngeneic models, tumor homografts are grown in immunocompetent hosts of the same genetic background, allowing testing of surrogate and cross-reactive immunotherapy agents.

Unlike syngeneic models, tumor homografts are never passaged in vitro. Instead they are passaged solely in vivo, preserving tumor architecture relevant to the original TME. And unlike traditional GEMM models, tumor growth can be synchronized across several animals to evaluate tumor response to treatment, making them amenable to large-scale studies.

Due to the patient-relevant mutations and TME provided by these models, tumor homografts help overcome the challenges faced by traditional syngeneic models, serving as the ideal complement in a large-scale screening program.

Summary

Large-scale immunotherapy screens provide a fast and efficient method to evaluate efficacy, PD effects, and to identify responder models or markers. By harnessing the variety of immunocompetent preclinical models available for these screens, you can be better prepared and progress your I/O program with more confidence.


Related Posts